Wellington Management Group LLP Boosts Stake in Artivion, Inc. $AORT

Key Points

• Wellington Management Group LLP increased its stake in Artivion by 4.1%, owning approximately 4.05% of shares valued at $42.46 million as of the first quarter.
• Artivion reported $0.24 earnings per share for the recent quarter, significantly exceeding analysts' expectations of $0.11, and its revenue increased by 15.3% year-over-year.
• Analysts have mixed outlooks on Artivion, with several raising price targets, resulting in an average target of $40.63 and a consensus rating of "Buy".

Wellington Management Group LLP increased its stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 4.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,727,408 shares of the company's stock after purchasing an additional 67,327 shares during the period. Wellington Management Group LLP owned 4.05% of Artivion worth $42,460,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Millennium Management LLC raised its position in shares of Artivion by 25.1% during the 4th quarter. Millennium Management LLC now owns 165,482 shares of the company's stock worth $4,731,000 after purchasing an additional 33,220 shares during the last quarter. Illinois Municipal Retirement Fund raised its position in shares of Artivion by 3.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock worth $504,000 after purchasing an additional 611 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Artivion by 2.4% in the 1st quarter. Principal Financial Group Inc. now owns 206,777 shares of the company's stock valued at $5,083,000 after acquiring an additional 4,749 shares during the last quarter. Deutsche Bank AG raised its holdings in Artivion by 45.1% in the 4th quarter. Deutsche Bank AG now owns 36,982 shares of the company's stock valued at $1,057,000 after acquiring an additional 11,501 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in Artivion by 27.9% in the 1st quarter. Invesco Ltd. now owns 341,656 shares of the company's stock valued at $8,398,000 after acquiring an additional 74,589 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Trading Up 0.1%

Shares of AORT stock traded up $0.06 on Friday, reaching $43.87. 342,981 shares of the stock were exchanged, compared to its average volume of 627,565. The stock has a market cap of $2.07 billion, a P/E ratio of -104.45 and a beta of 1.64. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52. The firm has a 50 day moving average of $35.07 and a two-hundred day moving average of $29.32. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $45.07.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.13. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm had revenue of $112.97 million during the quarter, compared to analysts' expectations of $107.96 million. Artivion's revenue for the quarter was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Buying and Selling at Artivion

In related news, CEO James P. Mackin sold 12,500 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $42.32, for a total transaction of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares of the company's stock, valued at approximately $36,089,776.56. This represents a 1.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John E. Davis sold 10,802 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total transaction of $471,723.34. Following the sale, the insider directly owned 208,778 shares of the company's stock, valued at approximately $9,117,335.26. This trade represents a 4.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 115,990 shares of company stock valued at $4,435,823 in the last quarter. Company insiders own 7.60% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on AORT. Stifel Nicolaus boosted their price target on Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a report on Friday, August 8th. Needham & Company LLC boosted their price target on Artivion from $45.00 to $50.00 and gave the company a "buy" rating in a report on Friday, August 22nd. JMP Securities boosted their price target on Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a report on Friday, August 8th. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Finally, Canaccord Genuity Group boosted their price target on Artivion from $35.00 to $41.00 and gave the company a "buy" rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $40.63.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.